Ramzy Reda M R, Goldman Ann S, Kamal Hussein A
Research & Training Center on Vectors of Diseases, Ain Shams University, Cairo, Egypt.
Filaria J. 2005 Aug 2;4:7. doi: 10.1186/1475-2883-4-7.
Lymphatic filariasis (LF) is targeted for global elimination. LF elimination programmes in different countries, including Egypt, are supported financially by national and international agencies. The national programme in Egypt is based on mass drug administration (MDA) of an annual dose of a combination of 2 drugs (DEC and albendazole) to all endemic villages. This study aimed primarily to estimate the Total and Government costs of two rounds of MDA conducted in Egypt in 2000 and 2001, the average cost per person treated, and the cost share of the different programme partners.
The Total costs reflect the overall annual costs of the MDA programme, and we defined Government costs as those expenditures made by the Egyptian government to develop, implement and sustain the MDA programmes. We used a generic protocol developed in coordination with the Emory Lymphatic Filariasis Support Center. Our study was concerned with all costs to the government, donors and other implementing parties. Cost data were retrospectively gathered from local, regional and national Ministry of Health and Population records. The total estimates for each governorate were based on data from a representative district for the governorate; these were combined with national programme data for a national estimate.
The overall Total and Government costs for treating approximately 1,795,553 individuals living in all endemic villages in the year 2000 were USD 3,181,000 and USD 2,412,000, respectively. In 2001, the number of persons treated increased (29%) and the Total costs were USD 3,109,000 while Government costs were USD 2,331,000. In 2000, the average Total and Government costs per treated subject were USD 1.77 and USD 1.34, respectively, however, these costs decreased to USD 1.34 and USD 1.00, respectively in 2001. The coverage rate was 86.0% in 2000 and it increased to 88.0% in 2001.
The Egyptian government provided 75.8% of all resources, as reflected in the Total cost estimates, and international agencies contributed the rest. Such data highlight both the commitment of the Egyptian government and the significance of the contributions of international bodies toward the LF elimination programme.
淋巴丝虫病（LF）是全球消除的目标疾病。包括埃及在内的不同国家的淋巴丝虫病消除计划得到了国家和国际机构的财政支持。埃及的国家计划基于对所有流行村庄的居民每年进行一次两种药物（乙胺嗪和阿苯达唑）联合用药的大规模药物给药（MDA）。本研究主要旨在估算2000年和2001年在埃及进行的两轮大规模药物给药的总成本和政府成本、人均治疗成本以及不同计划合作伙伴的成本分担情况。
总成本反映大规模药物给药计划的年度总成本，我们将政府成本定义为埃及政府为制定、实施和维持大规模药物给药计划所支出的费用。我们使用了与埃默里淋巴丝虫病支持中心协调制定的通用方案。我们的研究关注政府、捐助者和其他实施方的所有成本。成本数据是从地方、区域和国家卫生与人口部的记录中回顾性收集的。每个省的总估算基于该省一个代表性地区的数据；这些数据与国家计划数据相结合以得出全国估算。
2000年，治疗所有流行村庄中约1,795,553人的总成本和政府成本分别为3,181,000美元和2,412,000美元。2001年，治疗人数增加（29%），总成本为3,109,000美元，政府成本为2,331,000美元。2000年，每个治疗对象的平均总成本和政府成本分别为1.77美元和1.34美元，然而，这些成本在2001年分别降至1.34美元和1.00美元。2000年的覆盖率为86.0%，2001年增至88.0%。
如总成本估算所示，埃及政府提供了所有资源的75.8%，其余由国际机构提供。这些数据凸显了埃及政府的承诺以及国际机构对淋巴丝虫病消除计划贡献的重要性。
